PT2968302T - Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc - Google Patents

Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc

Info

Publication number
PT2968302T
PT2968302T PT147258123T PT14725812T PT2968302T PT 2968302 T PT2968302 T PT 2968302T PT 147258123 T PT147258123 T PT 147258123T PT 14725812 T PT14725812 T PT 14725812T PT 2968302 T PT2968302 T PT 2968302T
Authority
PT
Portugal
Prior art keywords
ribavirin
combination
antiviral agents
direct acting
treating hcv
Prior art date
Application number
PT147258123T
Other languages
English (en)
Inventor
M Bernstein Barry
M Menon Rajeev
Mensing Sven
M Awni Walid
Liu Wei
Dutta Sandeep
J Podsadecki Thomas
L Campbell Andrew
Wei Lin Chih
Wang Tianli
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2968302(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PT2968302T publication Critical patent/PT2968302T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
PT147258123T 2013-03-14 2014-03-14 Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc PT2968302T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2968302T true PT2968302T (pt) 2018-01-03

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147258123T PT2968302T (pt) 2013-03-14 2014-03-14 Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc

Country Status (27)

Country Link
US (1) US20140274934A1 (pt)
EP (4) EP3915559A1 (pt)
JP (3) JP6563894B2 (pt)
KR (2) KR20180045055A (pt)
CN (3) CN109908353A (pt)
AU (3) AU2014239322B2 (pt)
BR (1) BR112015020918A2 (pt)
CA (1) CA2901818C (pt)
CY (1) CY1121474T1 (pt)
DK (1) DK2968302T3 (pt)
EA (2) EA030482B1 (pt)
ES (1) ES2654109T3 (pt)
HK (2) HK1213191A1 (pt)
HR (1) HRP20171898T1 (pt)
HU (1) HUE036069T2 (pt)
IL (2) IL240445B (pt)
LT (1) LT2968302T (pt)
MX (1) MX2015012536A (pt)
NO (1) NO3090119T3 (pt)
PL (1) PL2968302T4 (pt)
PT (1) PT2968302T (pt)
RS (1) RS56735B1 (pt)
SG (2) SG10201709840UA (pt)
SI (1) SI2968302T1 (pt)
TW (2) TW202002979A (pt)
WO (1) WO2014152635A1 (pt)
ZA (1) ZA201705080B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EA030482B1 (ru) * 2013-03-14 2018-08-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
EP3060216A4 (en) * 2013-10-25 2017-06-21 Abbvie Inc. Methods for treating hcv
WO2015095572A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
DE202016008603U1 (de) 2016-01-08 2018-08-30 Entrust Datacard Corporation Kartendruckmechanismus mit Kartenrückführweg
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110053327A (ko) * 2008-06-10 2011-05-20 얀센 파마슈티카 엔.브이. 텔라프레비르 투여 방식
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2455376T3 (en) * 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
NZ608720A (en) * 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
UY34401A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
EA030482B1 (ru) * 2013-03-14 2018-08-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Also Published As

Publication number Publication date
EP2968302B9 (en) 2019-02-13
AU2014239322B2 (en) 2018-04-05
ZA201705080B (en) 2019-02-27
EP3733180A1 (en) 2020-11-04
PL2968302T3 (pl) 2018-04-30
EA201591701A1 (ru) 2016-02-29
AU2014239322A1 (en) 2015-08-27
TW201505633A (zh) 2015-02-16
HK1213191A1 (zh) 2016-06-30
RS56735B1 (sr) 2018-03-30
ES2654109T3 (es) 2018-02-12
WO2014152635A9 (en) 2014-12-11
SI2968302T1 (en) 2018-04-30
IL240445A0 (en) 2015-09-24
CY1121474T1 (el) 2020-05-29
CN109908353A (zh) 2019-06-21
DK2968302T3 (en) 2017-12-18
TWI678205B (zh) 2019-12-01
EA030482B1 (ru) 2018-08-31
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
CA2901818C (en) 2021-05-04
JP2016513703A (ja) 2016-05-16
CN105007921B (zh) 2018-12-11
AU2020201656A1 (en) 2020-03-26
TW202002979A (zh) 2020-01-16
LT2968302T (lt) 2017-12-27
HRP20171898T1 (hr) 2018-04-06
HUE036069T2 (hu) 2018-06-28
KR20150129035A (ko) 2015-11-18
JP2019214585A (ja) 2019-12-19
EP3318258A1 (en) 2018-05-09
EP3318258B1 (en) 2020-05-13
BR112015020918A2 (pt) 2017-07-18
KR20180045055A (ko) 2018-05-03
EP2968302B1 (en) 2017-09-06
IL240445B (en) 2019-07-31
AU2018202581A1 (en) 2018-05-10
AU2018202581B2 (en) 2019-12-05
PL2968302T4 (pl) 2018-04-30
EP3915559A1 (en) 2021-12-01
EP2968302A1 (en) 2016-01-20
JP2019167347A (ja) 2019-10-03
SG11201507361YA (en) 2015-10-29
US20140274934A1 (en) 2014-09-18
CN105007921A (zh) 2015-10-28
KR101853605B1 (ko) 2018-05-03
HK1255257A1 (zh) 2019-08-09
CA2901818A1 (en) 2014-09-25
SG10201709840UA (en) 2018-01-30
JP6563894B2 (ja) 2019-08-21
MX2015012536A (es) 2016-01-12
WO2014152635A1 (en) 2014-09-25
NO3090119T3 (pt) 2018-03-31
CN108187056A (zh) 2018-06-22

Similar Documents

Publication Publication Date Title
IL267927A (en) A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
HRP20181863T1 (hr) Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20170945T1 (hr) Sulfamoil-arilamidi i njihova uporaba kao lijekova za liječenje hepatitisa b
HK1217330A1 (zh) -苯基-氨甲酰衍生物及其作爲藥物用於治療乙型肝炎的用途
EP2953456A4 (en) TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2953462A4 (en) TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF HEPATITIS C
EP2953461A4 (en) TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b